CLINICAL TRIALS

Lymphoma (Non-Hodgkin) Clinical Trials in Kansas

10+ recruiting Lymphoma (Non-Hodgkin) trials in Kansas, sourced from ClinicalTrials.gov.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

ACTIVE NOT RECRUITINGPhase 2

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunother

NCT02143414 · Little Rock
ACTIVE NOT RECRUITINGPhase 2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other

NCT02978625 · Fairway
ACTIVE NOT RECRUITINGPhase 1

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphom

NCT03930953 · Overland Park
RECRUITINGPhase 1

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric anti

NCT06879340 · Westwood
RECRUITINGPhase 1

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R)

NCT06634589 · Westwood
ACTIVE NOT RECRUITINGPhase 2

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia.

NCT00792948 · Chanute
ACTIVE NOT RECRUITINGPhase 1

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule

NCT05397496 · Fairway
RECRUITINGPhase 2

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but

NCT06500273 · Hot Springs
ACTIVE NOT RECRUITINGPhase 2

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

NCT06425302 · Westwood
ACTIVE NOT RECRUITINGPhase 2

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of c

NCT01415752 · Lawrence

RECOMMENDED RESOURCES FOR LYMPHOMA (NON-HODGKIN)

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
💼

eHealth Insurance

Licensed Agents

Shop ACA health plans from top insurers. Licensed agents help you find coverage that works with clinical trial participation — at no cost to you.

Compare Plans Free →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Lymphoma (Non-Hodgkin) clinical trials in Kansas?

Yes. Clinicals AI lists 10+ recruiting Lymphoma (Non-Hodgkin) trials in Kansas sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Lymphoma (Non-Hodgkin) trial in Kansas?

Eligibility varies by study. Most trials require a confirmed Lymphoma (Non-Hodgkin) diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Lymphoma (Non-Hodgkin) clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.